Biogen Overview

  • Founded
  • 1978
Founded
  • Status
  • Public
  • Employees
  • 9,610
Employees
  • Stock Symbol
  • BIIB
Stock Symbol
  • Investments
  • 62
  • Share Price
  • $205.78
  • (As of Monday Closing)

Biogen General Information

Description

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Contact Information

Website
www.biogen.com
Formerly Known As
Biogen Idec
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 225 Binney Street
  • Cambridge, MA 02142
  • United States
+1 (781) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Biogen Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$205.78 $209.45 $200.36 - $468.55 $30.8B 147M 1.57M $10.44

Biogen Financials Summary

In Thousands,
USD 		TTM 31-Dec-2021 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 40,358,499 40,358,499 41,919,748 55,465,018
Revenue 10,981,700 10,981,700 13,444,600 14,377,900
EBITDA 2,475,500 2,475,500 5,685,200 7,658,000
Net Income 1,556,100 1,556,100 4,000,600 5,888,500
Total Assets 23,877,300 23,877,300 24,618,900 27,234,300
Total Debt 7,603,500 7,603,500 7,828,200 6,367,500
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Biogen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Biogen‘s full profile, request access.

Request a free trial

Biogen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer dru
Biotechnology
Cambridge, MA
9,610 As of 2021
000.00
000 0000-00-00
0&0

00000000

in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occa
000000000000000
Cambridge, MA
000 As of 0000
00000
000000000 00000

000000

rud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in r
0000 000000000
Bothell, WA
0000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Biogen Competitors (23)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ironwood Pharmaceuticals Formerly VC-backed Cambridge, MA 000 00000 000000000 00000
000000 Formerly VC-backed Bothell, WA 0000 00.000 000000000 00.000
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
0000000 0000000000 Formerly VC-backed San Diego, CA 00 00000 000000000 00000
0000000 0000000000 Corporate Backed or Acquired Allschwil, Switzerland 0000 00.000 00000000 00.000
You’re viewing 5 of 23 competitors. Get the full list »

Biogen Patents

  • 5,031

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 197

    Granted

  • 40

    Pending

  • 000

    Expiring in next 12 mo

Biogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210102939-A1 Assay for jc virus antibodies Pending 07-Oct-2019 000000000000
CA-3136536-A1 Process for preparing alpha-carboxamide pyrrolidine derivatives Pending 10-Apr-2019 0000000000
CA-3136426-A1 Processes for preparing alpha-carboxamide pyrrolidine derivatives Pending 10-Apr-2019 0000000000
AU-2020272766-A1 Anti-integrin antibodies and uses thereof Pending 08-Apr-2019 00000000000
CA-3136488-A1 Anti-integrin antibodies and uses thereof Pending 08-Apr-2019 C07K16/2842
To view Biogen’s complete patent history, request access »

Biogen Executive Team (88)

Name Title Board Seat Contact Info
Michel Vounatsos Chief Executive Officer & Board Member
Martin Dubuc Head, Digital Health & President, France
Michael Mcdonnell Chief Financial Officer & Executive Vice President
Paul Clancy Chief Financial Officer, Finance & Executive Vice President
Robin Kramer Chief Accounting Officer, Accounting & Senior Vice President
You’re viewing 5 of 88 executive team members. Get the full list »

Biogen Board Members (21)

Name Representing Role Since
Alexander Denner Ph.D Self Board Member 000 0000
Brian Posner Self Board Member 000 0000
Caroline Dorsa Biogen Board Member 000 0000
Eric Rowinsky MD Self Board Member 000 0000
George Scangos Ph.D Self Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 21 board members. Get the full list »

Biogen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biogen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Biogen‘s full profile, request access.

Request a free trial

Biogen Investments & Acquisitions (62)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 11-Jan-2021 00000 0000 00000 Drug Delivery
0000 00000000 31-Dec-2020 0000 00000 Biotechnology 000000 00
000000 000000 06-Oct-2020 00000 0000 0000 Other Pharmaceuticals and Biotechnology
000000 000000 22-Sep-2020 0000 00000 Biotechnology 000000 00
Autobahn (Drug Discovery) 09-Jun-2020 Early Stage VC 000.00 Drug Discovery
You’re viewing 5 of 62 investments and acquisitions. Get the full list »

Biogen Subsidiaries (2)

Company Name Industry Location Founded
AliveGen USA Biotechnology Thousand Oaks, CA 2014
0000000 Biotechnology NC 0000
To view Biogen’s complete subsidiaries history, request access »

Biogen Exits (28)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000 00000000000 30-Mar-2017 00000 00000 00 0000 Completed
  • 8 buyers
00000000 000000000 18-Feb-2016 00000 00000 00 0000 Completed
  • 7 buyers
00000 000000000000 06-Jan-2016 00000 00000 00 000.00 Completed
  • 3 buyers
00000 00 03-Nov-2015 00000 00000 00 000.00 Completed
  • 6 buyers
True North Therapeutics 17-Jun-2014 Later Stage VC 0000 Completed
  • 8 buyers
You’re viewing 5 of 28 exits. Get the full list »